Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Adams Cancer Center
mi
from
Gettysburg, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Texas Oncology, PA at Harris Center HEB
mi
from
Bedford, TX
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Texas Oncology, PA at Harris Center HEB
mi
from
Bedford, TX
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital
mi
from
Fort Worth, TX
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Memorial Hermann Hospital - Memorial City
mi
from
Houston, TX
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Memorial Hermann Hospital - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land
mi
from
Sugar Land, TX
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
mi
from
Murray, UT
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
mi
from
Ogden, UT
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
mi
from
Ogden, UT
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
NSMC Cancer Center - Peabody
mi
from
Danvers, MA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
NSMC Cancer Center - Peabody
mi
from
Danvers, MA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Billings Clinic - Downtown
mi
from
Billings, MT
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Billings Clinic - Downtown
mi
from
Billings, MT
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
York Cancer Center at Apple Hill Medical Center
mi
from
York, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
London Regional Cancer Program at London Health Sciences Centre
mi
from
London,
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
London Regional Cancer Program at London Health Sciences Centre
mi
from
London,
Click here to add this to my saved trials
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
Safety and Feasibility Evaluation of the MRI-based Tracking of Alpha-type-1 Dendritic Cell Vaccines in Patients With Colorectal Cancer
Status: Enrolling
Updated:  9/25/2017
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)
Safety and Feasibility Evaluation of the MRI-based Tracking of Alpha-type-1 Dendritic Cell Vaccines in Patients With Colorectal Cancer
Status: Enrolling
Updated: 9/25/2017
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Status: Enrolling
Updated:  9/25/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Status: Enrolling
Updated: 9/25/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy
A Phase I/IIa Safety and Efficacy Study of Topical Phenylephrine Applied to Oral Mucosa in Bone Marrow Transplant Patients Receiving Cytoxan Plus Total Body Irradiation
Status: Enrolling
Updated:  9/25/2017
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy
A Phase I/IIa Safety and Efficacy Study of Topical Phenylephrine Applied to Oral Mucosa in Bone Marrow Transplant Patients Receiving Cytoxan Plus Total Body Irradiation
Status: Enrolling
Updated: 9/25/2017
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
Lakeland Regional Health Care/Cancer Center
mi
from
Lakeland, FL
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
Lakeland Regional Health Care/Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
The West Clinic, PC
mi
from
Memphis, TN
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated:  9/25/2017
US Oncology / Texas Oncology, P.A.
mi
from
Houston, TX
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Enrolling
Updated: 9/25/2017
US Oncology / Texas Oncology, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
A Phase 2 Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  9/25/2017
Hillman Cancer Center
mi
from
Pittsburgh, PA
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
A Phase 2 Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 9/25/2017
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma
Status: Enrolling
Updated:  9/25/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma
Status: Enrolling
Updated: 9/25/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel Chemotherapy in Patients With Stage I-IIb Papillary Serous, Clear Cell and Endometrioid Endometrial Cancer With High-Intermediate Risk Factors
Status: Enrolling
Updated:  9/25/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel Chemotherapy in Patients With Stage I-IIb Papillary Serous, Clear Cell and Endometrioid Endometrial Cancer With High-Intermediate Risk Factors
Status: Enrolling
Updated: 9/25/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Outcomes Study
Status: Enrolling
Updated:  9/25/2017
George Washington University
mi
from
Rockville, MD
Diabetes Prevention Program Outcomes Study
Diabetes Prevention Program Outcomes Study
Status: Enrolling
Updated: 9/25/2017
George Washington University
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Louisville, KY
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Boston, MA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Fullerton, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Glendale, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
La Jolla, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Riverside, CA
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Orange City, FL
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Quincy, IL
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Quincy, IL
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Northport, NY
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Northport, NY
Click here to add this to my saved trials
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated:  9/26/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status: Enrolling
Updated: 9/26/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials